Literature DB >> 9142107

How immune-based interventions can change HIV therapy.

G Pantaleo1.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9142107     DOI： 10.1038/nm0597-483

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

1.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  In vivo analysis of Fas/FasL interactions in HIV-infected patients.

Authors:  A D Badley; D H Dockrell; A Algeciras; S Ziesmer; A Landay; M M Lederman; E Connick; H Kessler; D Kuritzkes; D H Lynch; P Roche; H Yagita; C V Paya
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

4.  Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients.

Authors:  G Hittinger; C Poggi; E Delbeke; N Profizi; A Lafeuillade
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

5.  Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection.

Authors:  V Vieillard; S Jouveshomme; N Leflour; E Jean-Pierre; P Debre; E De Maeyer; B Autran
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 6.  A risk-benefit assessment of HIV protease inhibitors.

Authors:  G J Moyle; B G Gazzard
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

7.  Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.

Authors:  H F Günthard; J K Wong; C C Ignacio; J C Guatelli; N L Riggs; D V Havlir; D D Richman
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro.

Authors:  C A Van Baalen; M Schutten; R C Huisman; P H Boers; R A Gruters; A D Osterhaus
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Single-cell analysis of lymphokine imbalance in asymptomatic HIV-1 infection: evidence for a major alteration within the CD8+ T cell subset.

Authors:  A E Sousa; R M Victorino
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

10.  Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: a new approach To chemotherapy against human immunodeficiency virus type 1.

Authors:  A Achour; J C Landureau; R Salerno-Goncalves; R Salerno-Concalves; J C Mazière; D Zagury
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.